Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicamen BiotechBOM:531146 +0.65%58 Gross Margin % is 46.91% as of Mar. 2026, which is 33% above its 10-year median of 35.14. GuruFocus rates BOM:531146 with a GF Score™ of 58/100 and a GF Value™ of ₹510.73 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, Medicamen Biotech ranks better than 50.05% on this metric.
The historical rank and industry rank for Medicamen Biotech's Gross Margin % or its related term are showing as below:
BOM:531146'
s Gross Margin % Range Over the Past 10 Years
Min: 25.62 Med: 35.14 Max: 48.54
Current: 48.54
During the past 13 years, the highestGross Margin % of Medicamen Biotech was 48.54%. The lowest was 25.62%. And the median was 35.14%.
BOM:531146's Gross Margin % is ranked better than 50.05% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:531146: 48.54
Medicamen Biotech had a gross margin of 46.91% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Medicamen Biotech was 8.60% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medicamen Biotech had a gross margin of 46.91% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medicamen Biotech Gross Margin % Related Terms
Medicamen Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Medicamen Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Biotech Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medicamen Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medicamen Biotech (BOM:531146) has a Gross Margin % of 46.91% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Medicamen Biotech and its competitors. This is 33% above median its historical median of 35.14. Over the past decade, Medicamen Biotech's Gross Margin % has ranged from 25.62 to 48.54. According to the industry distribution chart, Medicamen Biotech ranks #471 out of 943 companies in the Drug Manufacturers industry, placing it in the top 49.9%.
Is Medicamen Biotech's Gross Margin % too high?
Medicamen Biotech's current Gross Margin % of 46.91% is 33% above median its 10-year median of 35.14. Over the past 10 years, this metric has ranged from a low of 25.62 to a high of 48.54. The Drug Manufacturers industry median Gross Margin % is 48.54. Medicamen Biotech's value of 46.91% is 3.4% below this industry median. Based on the distribution chart, Medicamen Biotech ranks #471 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medicamen Biotech has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicamen Biotech's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medicamen Biotech ranks #471 out of 943 companies for Gross Margin %. This puts Medicamen Biotech in the upper half of its industry. The industry median Gross Margin % is 48.54. Medicamen Biotech's value of 46.91% is 3.4% below this benchmark. Historically, Medicamen Biotech's own Gross Margin % has ranged from 25.62 to 48.54 over the past decade. While the company's 10-year median is 35.14 vs. the industry median of 48.54, Medicamen Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicamen Biotech's current Gross Margin % of 46.91% is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medicamen Biotech and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicamen Biotech's current Gross Margin % is 46.91%, which is 33% above median its own 10-year median of 35.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicamen Biotech (BOM:531146) is currently considered Possible Value Trap. The stock's GF Value™ is ₹510.73, compared to a current price of ₹238.45 — trading 53.3% below its estimated fair value. The current Gross Margin % is 46.91%, which is 33% above median its 10-year median of 35.14 and 3.4% below the Drug Manufacturers industry median of 48.54. Medicamen Biotech's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medicamen Biotech (BOM:531146), the current Gross Margin % is 46.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicamen Biotech (BOM:531146) Overvalued in 2026?
Based on GuruFocus' analysis, Medicamen Biotech stock appears to be undervalued.
The current stock price of ₹238.45 is trading 53.3% below its estimated GF Value™ of ₹510.73.
GuruFocus considers Medicamen Biotech to be Possible Value Trap.
Key valuation signals for BOM:531146:
Gross Margin %: 46.91% (33% above median its 10-year median of 35.14)
GF Value™: ₹510.73 vs. price of ₹238.45 (53.3% below fair value)
Industry Position: 3.4% below the Drug Manufacturers median (#471 of 943)
No single metric tells the full story. See the BOM:531146 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. It generates revenue from the sale of pharmaceutical products.
58GF Score
Get the complete analysis for BOM:531146
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531146 has been successfully added to your 
